Approved ribonucleic acid (RNA) medicines are already treating spinal muscular atrophy, inherited muscle and nerve disorders, rare metabolic diseases, bleeding disorders, eye disease, amyloidosis, and high cholesterol. In the United States, approved RNA medicines are led by antisense oligonucleotides and small interfering RNA drugs, with recent approvals expanding the range of treatable conditions.
These treatments are no longer limited to laboratory research or clinical trial access. You can now find RNA-based drugs in neurology, cardiology, hematology, ophthalmology, and rare disease care. Knowing how the drug classes differ helps you understand which medicines are available, what they treat, and what treatment may involve.
What Are RNA Therapeutics?
RNA therapeutics are medicines designed to interact with RNA, the genetic messenger that helps cells produce proteins. They can reduce a harmful protein, change how a protein is assembled, or bind to a disease-related target.
Your DNA stores genetic instructions, and messenger RNA carries copies of those instructions to the cell’s protein-making machinery. Many RNA medicines act between those two steps. Instead of removing or permanently changing a gene, they modify how its instructions are processed or used.
This feature makes RNA useful for diseases tied to a known protein or genetic error. A drug can be designed to recognize a specific RNA sequence, giving it a more targeted job than many traditional medicines. Delivery remains a major consideration because the medicine must reach the correct tissue and stay intact long enough to work.
The field also has a longer history than many people assume. Fomivirsen, sold as Vitravene, became the first RNA-targeted drug approved in the United States in 1998. It was later withdrawn after demand fell, rather than because RNA medicines as a class had failed.
How Do The Main RNA Medicine Classes Work?
The main non-vaccine classes are antisense oligonucleotides, small interfering RNA medicines, and aptamers. They use different biological mechanisms, delivery methods, and treatment schedules.
An antisense oligonucleotide (ASO) is a short, synthetic strand designed to bind to a selected RNA sequence. Some ASOs cause the targeted RNA to break down, reducing production of a harmful protein. Others change RNA splicing, which is the editing process cells use before making a protein.
Small interfering RNA (siRNA) medicines use RNA interference, a natural cellular process that identifies and destroys selected messenger RNA. Many approved siRNA drugs act in the liver because delivery systems can direct them there efficiently. This makes the class useful when a disease-causing or disease-related protein is produced mainly by liver cells.
An RNA aptamer folds into a shape that binds to a selected molecule. It acts more like a precision binding agent than a gene-silencing drug. Messenger RNA (mRNA) also has approved preventive vaccine applications, but non-vaccine mRNA therapeutics have not yet become part of routine prescribing.
Which Approved RNA Medicines Are Available Now?
Current United States approvals include 11 antisense medicines, eight siRNA medicines, and one clinically available RNA aptamer. Approval does not mean every product is widely prescribed, because eligibility, commercial availability, specialist experience, and competing treatments differ.
Current United States RNA Medicines By Class
|
Class |
Medicine |
Main Approved Use |
Initial FDA Approval
|
|
ASO |
Spinraza (nusinersen) |
Spinal muscular atrophy |
2016 |
|
ASO |
Exondys 51 (eteplirsen) |
Duchenne muscular dystrophy eligible for exon 51 skipping |
2016 |
|
ASO |
Tegsedi (inotersen) |
Hereditary transthyretin-mediated amyloidosis with polyneuropathy |
2018 |
|
ASO |
Vyondys 53 (golodirsen) |
Duchenne muscular dystrophy eligible for exon 53 skipping |
2019 |
|
ASO |
Viltepso (viltolarsen) |
Duchenne muscular dystrophy eligible for exon 53 skipping |
2020 |
|
ASO |
Amondys 45 (casimersen) |
Duchenne muscular dystrophy eligible for exon 45 skipping |
2021 |
|
ASO |
Qalsody (tofersen) |
Superoxide dismutase 1 amyotrophic lateral sclerosis |
2023 |
|
ASO |
Wainua (eplontersen) |
Hereditary transthyretin-mediated amyloidosis with polyneuropathy |
2023 |
|
ASO |
Tryngolza (olezarsen) |
Familial chylomicronemia syndrome and certain adults with severe hypertriglyceridemia |
2024 |
|
ASO |
Dawnzera (donidalorsen) |
Prevention of hereditary angioedema attacks |
2025 |
|
ASO |
Zanvastro (zilganersen) |
Alexander disease |
2026 |
|
siRNA |
Onpattro (patisiran) |
Hereditary transthyretin-mediated amyloidosis with polyneuropathy |
2018 |
|
siRNA |
Givlaari (givosiran) |
Acute hepatic porphyria |
2019 |
|
siRNA |
Oxlumo (lumasiran) |
Primary hyperoxaluria type 1 |
2020 |
|
siRNA |
Leqvio (inclisiran) |
Low-density lipoprotein cholesterol reduction in eligible adults |
2021 |
|
siRNA |
Amvuttra (vutrisiran) |
Transthyretin-mediated amyloidosis with polyneuropathy or cardiomyopathy |
2022 |
|
siRNA |
Rivfloza (nedosiran) |
Primary hyperoxaluria type 1 |
2023 |
|
siRNA |
Qfitlia (fitusiran) |
Bleeding prevention in eligible patients with hemophilia A or B |
2025 |
|
siRNA |
Redemplo (plozasiran) |
Triglyceride reduction in familial chylomicronemia syndrome |
2025 |
|
RNA aptamer |
Izervay (avacincaptad pegol) |
Geographic atrophy secondary to age-related macular degeneration |
2023 |
The United States Food and Drug Administration (FDA) first approved Onpattro in 2018 as the first siRNA medicine. Spinraza, approved two years earlier, showed how an ASO could modify RNA splicing and treat spinal muscular atrophy. More recent additions have brought RNA treatment into bleeding prevention, hereditary swelling disorders, triglyceride management, and Alexander disease.
European availability is not always identical to United States availability. The European Medicines Agency (EMA) has authorized Waylivra (volanesorsen), an ASO for selected adults with familial chylomicronemia syndrome, but it does not have FDA approval. Your location can affect which RNA drug is licensed, marketed, and reimbursed.
Which Diseases Can RNA Drugs Treat Today?
RNA drugs currently treat a mix of neurological, muscular, metabolic, cardiovascular, blood, liver, and eye conditions. Rare genetic diseases still account for much of the list, but cholesterol and triglyceride medicines are widening the potential patient population.
In neurology, Spinraza changes the processing of survival motor neuron 2 RNA so that the body can produce more functional survival motor neuron protein. Qalsody targets superoxide dismutase 1 RNA in people with a specific inherited form of amyotrophic lateral sclerosis. Zanvastro reduces production of glial fibrillary acidic protein in pediatric and adult patients with Alexander disease.
Duchenne muscular dystrophy has several mutation-specific ASO treatments. Exondys 51, Vyondys 53, Viltepso, and Amondys 45 promote exon skipping, allowing eligible patients to produce a shorter form of dystrophin. A genetic test is needed because each drug applies only to mutations suited to its targeted exon.
Amyloidosis has one of the largest groups of approved RNA-based options. Onpattro, Tegsedi, Wainua, and Amvuttra reduce production of transthyretin, a protein that can form damaging deposits. Amvuttra’s approved uses now include polyneuropathy and cardiomyopathy associated with transthyretin-mediated amyloidosis.
Liver-directed RNA silencing also supports treatment of acute hepatic porphyria, primary hyperoxaluria type 1, familial chylomicronemia syndrome, and high low-density lipoprotein cholesterol. Leqvio stands out because it addresses a common cardiovascular risk factor rather than an ultra-rare disorder. Tryngolza has also moved beyond its original rare-disease use into treatment for eligible adults with severe hypertriglyceridemia.
How Are RNA Medicines Given And Monitored?
Most approved RNA medicines are given by an injection, infusion, spinal procedure, or injection into the eye. There is no approved oral RNA pill among the medicines listed here.
Subcutaneous injections under the skin are common. Leqvio is administered at the start of treatment, again after three months, and then every six months. Amvuttra and Redemplo are given every three months, and Dawnzera can be administered every four or eight weeks based on the prescribed regimen.
Some drugs require specialist procedures. Spinraza, Qalsody, and Zanvastro are delivered into the fluid surrounding the spinal cord through intrathecal administration. Onpattro is given by intravenous infusion, and Izervay is injected into the eye by an eye-care specialist.
Monitoring depends on the drug and disease. Your care plan may include blood counts, liver tests, kidney tests, neurological assessments, eye examinations, vitamin monitoring, or checks for injection and infusion reactions. The official prescribing information defines the required schedule, precautions, and situations in which treatment should be paused or stopped.
Repeat treatment matters because most current RNA drugs do not permanently alter your DNA. Their effects can fade as the body produces new RNA and clears the medicine. Staying on schedule helps maintain the intended level of gene silencing or splicing modification.
Are RNA Medicines Cures, And What Is Known About Safety?
Most RNA medicines are ongoing treatments rather than permanent cures. They can reduce harmful protein production, improve RNA processing, or slow disease activity, but repeat dosing is usually needed.
The word “approved” means regulators reviewed evidence supporting a medicine’s benefits, risks, manufacturing quality, and proposed use. Some RNA medicines received accelerated approval based on a measure considered reasonably likely to predict clinical benefit. Confirmatory research may continue after approval, along with routine safety monitoring and disease registries.
Safety considerations differ sharply between products. A liver-targeted injection cannot be assumed to have the same risks as an intrathecal medicine or an injection into the eye. The treated disease, target protein, delivery route, dose, and effects outside the intended tissue all influence monitoring.
You should also separate class-wide concerns from drug-specific warnings. One ASO may require close platelet or kidney monitoring, and another may have a different set of precautions. Your specialist should review the current label, other medicines, laboratory results, and treatment alternatives before prescribing an RNA therapy.
Longer follow-up remains valuable because several products serve small patient populations and have had fewer years of routine use than older drug classes. Post-approval monitoring can identify uncommon side effects and refine how doctors select and monitor patients. It does not mean the medicine is unapproved or available only through an experiment.
How Can You Access And Pay For An RNA Therapy?
Access usually begins with a specialist who can confirm that you meet the exact approved criteria. Diagnosis alone may not be enough because genetic subtype, age, previous treatment, disease stage, or laboratory results can determine eligibility.
A neurologist may order genetic testing before prescribing a mutation-specific Duchenne muscular dystrophy drug. An amyloidosis team may confirm the type of transthyretin disease and whether the main problem is polyneuropathy, cardiomyopathy, or a combination. Lipid specialists must also distinguish familial chylomicronemia syndrome from more common causes of high triglycerides.
Many RNA medicines are orphan drugs developed for small patient populations. Insurance review can involve prior authorization, documentation of genetic results, confirmation of specialist care, and proof that the prescribed use matches the current label. Treatment given at a hospital, infusion center, clinic, or specialty pharmacy may also be covered under different parts of a health plan.
You can ask the prescribing team to check coverage before treatment is scheduled. Useful questions include which tests are required, where the drug must be administered, whether travel is involved, and what laboratory monitoring is covered. Manufacturer assistance services and independent patient organizations may help eligible patients understand insurance requirements or locate qualified treatment centers.
What RNA Medicines Are Already Approved?
- ASOs: Spinraza, Exondys 51, Tegsedi, Vyondys 53, Viltepso, Amondys 45, Qalsody, Wainua, Tryngolza, Dawnzera, Zanvastro
- siRNA: Onpattro, Givlaari, Oxlumo, Leqvio, Amvuttra, Rivfloza, Qfitlia, Redemplo
- RNA aptamer: Izervay
RNA Treatment Has Already Entered Routine Care
Approved RNA medicines now give specialists practical ways to alter splicing, silence disease-related genes, and block selected molecular targets. You can see their greatest current reach in rare neurological, muscular, metabolic, and inherited disorders, yet cholesterol and triglyceride treatments show that the field is moving into larger patient groups. Most options still require injections, specialist oversight, repeat dosing, and condition-specific monitoring. The right question is no longer whether RNA can function as medicine, but whether a particular RNA drug matches your diagnosis, genetic results, treatment goals, and access needs. Review the latest prescribing information with your care team because indications and availability can change.
References
- United States Food and Drug Administration: Novel Drug Approvals
- United States Food and Drug Administration: Novel Drug Approvals for 2024
- United States Food and Drug Administration: Novel Drug Approvals for 2025
- United States Food and Drug Administration: Novel Drug Approvals for 2026
- United States Food and Drug Administration: RNA-Based Medicine and Small Interfering RNA
- DailyMed: Current Prescribing Information
- European Medicines Agency: Medicines Database
- European Medicines Agency: Waylivra
- United States Food and Drug Administration: Zanvastro Approval
- United States Food and Drug Administration: Qfitlia Approval.
Maurizio Chiriva Internati (DBSc, PhDs) is a cancer immunologist and biotech entrepreneur with 20+ years in immuno-oncology. Co-founder and former CEO of Kiromic BioPharma (NASDAQ: KRBP), he has led AI-driven target discovery and translational programs, and has served on faculty at MD Anderson and Texas Tech.
